Alnylam Pharmaceuticals (ALNY) Advances Diabetes Drug Into Phase 2 Trial [Yahoo! Finance]
Alnylam Pharmaceuticals, Inc. (ALNY)
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.alnylam.com/investor-overview
Company Research
Source: Yahoo! Finance
On April 17, 2026, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) provided an update on its experimental drug, ALN-4324. Currently in its Phase 2 clinical trial, the company's experimental RNAi therapeutic drug aims at treating type 2 diabetes. The trial involves a triple-blind, placebo-controlled study that evaluates the impact of a single subcutaneous injection on insulin sensitivity. Formally initiated in March 2026, the trial reflects Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)'s strategic expansion from rare diseases into the high-demand metabolic market. If the trial turns out to be successful, it will elevate the company's position as a formidable competitor, on par with industry leaders like Eli Lilly and Novo Nordisk. In a separate event, on April 13, 2026, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) saw an adjustment to its price target from Truist. The firm lowered its price target from $515 to $505 while maintaining a Buy rating on the stock. Truist provided the update as
Show less
Read more
Impact Snapshot
Event Time:
ALNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALNY alerts
High impacting Alnylam Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ALNY
News
- CureVac sues Moderna for patent infringement over COVID-19 vaccines [Yahoo! Finance]Yahoo! Finance
- CureVac sues Moderna for patent infringement over COVID-19 vaccines [Yahoo! Finance Canada]Yahoo! Finance Canada
- Alnylam Pharmaceuticals: Cutting-Edge Pharma Stock Still Feels A Little Overvalued [Seeking Alpha]Seeking Alpha
- BXMT Q2 2025 Earnings Call Transcript [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Recent Choppy Trading And Rich P/E Multiple [Yahoo! Finance]Yahoo! Finance
ALNY
Earnings
- 2/12/26 - Beat
ALNY
Sec Filings
- 4/29/26 - Form SCHEDULE
- 4/7/26 - Form 4
- 4/7/26 - Form 3
- ALNY's page on the SEC website